- cafead May 13, 2024 at 10:32: PM
via AbbVie is wading into the waters of psychedelics, penning a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen therapies for psychiatric disorders.
The two companies have agreed to research and develop a portfolio of therapeutics using Gilgamesh’s research platform designed to discover novel neuroplastogens—compounds that improve neuroplasticity. Under the deal, AbbVie will have the option to lead development and commercialization activities.
article source
The two companies have agreed to research and develop a portfolio of therapeutics using Gilgamesh’s research platform designed to discover novel neuroplastogens—compounds that improve neuroplasticity. Under the deal, AbbVie will have the option to lead development and commercialization activities.
article source